Everything below concerns GHRH analogue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
== Connections with Morocco == Belgian Justice Minister Vincent Van Quickenborne described Morocco as a nation known for interfering in the EU. He said the investigation was focusing on multiple subjects, including the EU-Morocco trade agreements and the fisheries agreement. A report by the Financial Times revealed that the Pier Antonio Panzeri received bribes, gifts and luxury hotel stays from the Moroccan government. The former Italian MEP had ties with Moroccan officials since he was the head of the European Parliament's EU-Maghreb delegation. Records revealed that during his time in the parliament Panzeri supported decisions favoring the Moroccan government. He had raised a request to the European Commission for allocation of more funds for Morocco, and also voted in favor of Morocco's trade agreement with the EU and the fisheries agreement. Panzeri received secret payments from Morocco's ambassador to Poland Abderrahim Atmoun through the NGOs. Panzeri and Atmoun worked together as co-chairs of the Morocco-EU joint parliamentary committee. Panzeri admitted Atmoun provided financial help for his 2014 electoral campaign, including covering a €50,000 cost of a party in Milan. In 2014, Moroccan King Mohammed VI awarded Panzeri with the third class Order of Ouissam Alaouite for his services to Rabat. Atmoun received the same decoration at the same event. Belgium has drafted a request for a European arrest warrant for Atmoun who is believed to have received funds from Moroccan officials to bribe members of European Parliament to favour Morocco.
=== Bone marrow barrier === The blood vessels of the bone marrow constitute a barrier, inhibiting immature blood cells from leaving the marrow. Only mature blood cells contain the membrane proteins, such as aquaporin and glycophorin, that are required to attach to and pass the blood vessel endothelium. Hematopoietic stem cells may also cross the bone marrow barrier, and may thus be harvested from blood.
The common death adder (Acanthophis antarcticus) is a highly venomous snake species with a 50–60% untreated mortality rate. It is also the fastest striking venomous snake in the world. A death adder can go from a strike position, to strike and envenoming their prey, and back to strike position again, in less than 0.15 seconds. The SC LD50 value is 0.4 mg/kg and the venom yield per bite can range anywhere from 70–236 mg. Unlike other snakes that flee from approaching humans crashing through the undergrowth, common death adders are more likely to sit tight and risk being stepped on, making them more dangerous to the unwary bushwalker. They are said to be reluctant to bite unless actually touched.
Sources: en.wikipedia.org
=== Immune modulation and infection === Semaglutide appears to influence the immune system through a complex gut-brain-immune network. The activation of central neuronal GLP-1 receptors by semaglutide signals through the endogenous opioid and adrenergic systems to suppress peripheral inflammation. In conditions like obesity, compromised gut barriers can allow bacterial lipopolysaccharides (LPS, or endotoxins) to enter the bloodstream, triggering severe immune responses via TLR4 receptors. Semaglutide blunts this LPS-induced release of pro-inflammatory cytokines. Moreover, in animal models of polymicrobial sepsis, semaglutide has been shown to decrease bacterial loads in multiple organs and promote the homeostasis of immunoregulatory regulatory T cells (Tregs) via the activation of FOXP3.
Heavy metal contamination of land by industry. These can then be transported into water bodies and be taken up by living organisms such as animals and plants. PAHs (Polycyclic Aromatic Hydrocarbon) in large bodies of water contaminated by oil spills or leaks. Many of the PAHs are carcinogens and are extremely toxic. They are regulated by concentration (ppb) using environmental chemistry and chromatography laboratory testing. Nutrients leaching from agricultural land into water courses, which can lead to algal blooms and eutrophication. Urban runoff of pollutants washing off impervious surfaces (roads, parking lots, and rooftops) during rain storms. Typical pollutants include gasoline, motor oil and other hydrocarbon compounds, metals, nutrients and sediment (soil). Organometallic compounds. Radiochemicals.
=== Pharmacokinetics === Nadolol is classified as a beta blocker with low lipophilicity and hence lower potential for crossing the blood–brain barrier. This in turn may result in fewer effects in the central nervous system as well as fewer neuropsychiatric side effects.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.